The sponsor might be interested in determining the effect of including Site A on key trial markers (e.g., feasibility, cost, and total clinical trial duration) by allowing for up to an 8-week delay in Site A's initiation.
This is based on the cumulative binomial distribution of 30 trials (markers) each one associated to a probability of being informative (success of the trial) of 0.32.
Several critical issues, including scientific rationale, clinical trial design, marker assessment methods, cost and feasibility have to be carefully considered in the validation of biomarkers through clinical research before they can be routinely integrated into clinical practice.
Prior to walking trials, reflective markers were affixed to the hip, knee, ankle, heel, hallux, 1st metatarsal head and shoulder.
Prior to trackway trials, reflective markers were affixed to the hip, knee, ankle, heel, hallux, 1st metatarsal head, and shoulder.
Except in two trials, laboratory markers of safety (including haematological and biochemical indices) were not available.
Due to conflicting data and a low proportion of prospectively designed trials, urine markers are not recommended to replace cystoscopy in current guidelines [ 2, 8].
Although we have focused on biomarker-strategy designs, the general concept of allowing for a change in biomarker could be used in other biomarker designs also, such as enrichment trials and marker-by-treatment interaction designs.
Since the 1992 American College of Chest Physicians/Society of Critical Care Medicine (ACCP/SCCM) consensus conference on sepsis definitions [ 2], predefined sepsis criteria for patient enrolment in clinical trials and markers of organ dysfunction have been increasingly applied [ 1].
Prior to trials, reflective markers were placed in line with the sternum and at the tip of the claw of the birds to allow determination of the start and end of a jump, respectively.
